吉西他滨序贯化放疗在非小细胞肺癌中的疗效及不良反应分析

目的探讨吉西他滨序贯化放疗在非小细胞肺癌中的疗效及不良反应。方法对2016年3月～2017年3月来我院就诊的非小细胞肺癌患者资料进行回顾性分析。所有患者共62例,均为病理和临床活检被确诊为非小细胞肺癌患者,给予所有患者吉西他滨序贯化疗方案进行治疗,并按照世界卫生组织的标准评价患者的临床疗效以及不良反应对患者进行随访,观察患者的生存周期。结果本次研究共62例患者,62例可评价临床疗效,其中42例(67.7%)病情得到缓解,19例(30.6%)病情基本稳定,1例(1.7%)病情无改善,持续发展。生存期为4.8～26.5个月,平均(14.3±5.9)个月。不良反应发生率为64.5%,主要包括21例血液毒性现象,19例消化道症状。结论吉西他滨序贯化放疗对非小细胞肺癌患者有一定的临床应用价值,可以延长患者生存周期,但存在一定的不良反应,因此,临床上使用需要考虑患者耐受问题。

Effectiveness and adverse reaction of gemcitabine sequential chemotherapy followed by radiotherapy in patients with non-small-cell lung cancer

Objective To investigate the effectiveness and adverse reaction of gemcitabine sequential chemotherapy followed by radiotherapy in patients with non-small-cell lung cancer(NSCLC).Methods Records of patients with NSCLC in our hospital from March 2016 to March 2017 were analyzed retrospectively.There were 62 patients diagnosed as NSCLC by pathological examination and clinical biopsy.All the patients were treated with gemcitabine sequential chemotherapy.The clinical effectiveness and adverse reaction in patients were assessed according to WHO guideline.Follow-up visit was paid to observe patients''survival.Results 62 patients were involved and the clinical effectiveness could be assessed in all of them.Out of them,42 patients(67.7%)got remission,19 patients(30.6%)were with compar atively stable disease and 1 patient(1.7%)did not get improved and with progressive disease.Survival ranged from 4.8 to 26.5 months,averaged(14.3±5.9)months.The incidence of adverse reaction was 64.5%,mainly including 21 cases with hematological toxicity and 19 cases with alimentary symptoms.Conclusion Gemcitabine sequential chemotherapy followed by radiotherapy was clinical valuable in patients with NSCLC and could extend the survival of patients.The tolerance of patients should be considered when applied in clinic since there would be some adverse reaction.